/FUDANZHANGJIANG - Announcement of Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. on participating in the 2026 Semi-annual Science and Technology Innovation Board Innovative Drug Industry Collective Performance Briefing Meeting
NEWS

4d ago

FUDANZHANGJIANG - Announcement of Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. on participating in the 2026 Semi-annual Science and Technology Innovation Board Innovative Drug Industry Collective Performance Briefing Meeting

HKEXnews
2026/09/04[Overseas Regulatory Announcement - Other]

Overseas regulatory announcement

This announcement is issued by Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. (the "Company") in accordance with Rule 13.10(B) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Hereby is set out the "Announcement of Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. on participating in the 2026 Semi-annual Science and Technology Innovation Board Innovative Drug Industry Collective Performance Briefing" published on the website of the Shanghai Stock Exchange for reference only. This document and its disclosure content are prepared and published in accordance with PRC laws and regulations and relevant domestic regulatory requirements.

By order of the board of directors

Zhao Dajun

Chairman

As at the date of this announcement, the Board of Directors includes the following individuals:

Mr. Zhao Dajun (Executive Director)

Ms. Xue Yan (Executive Director)

Mr. Zhong Tao (Non-executive Director)

Ms. Yu Xiaoyang (Non-executive Director)

Mr. Wang Hongguang (Independent Non-executive Director) Mr. Lin Zhaorong (Independent Non-executive Director) Mr. Xu Peilong (Independent Non-executive Director) Ms. Qu Yanan (Employee Director)

Shanghai, China

September 4, 2026

*For identification only

Securities code: 688505 Securities abbreviation: Fudan Zhangjiang Announcement Number: Lin 2026-024

Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd.

About participating in the 2026 Semi-annual Science and Technology Innovation Board Innovation Drug Industry

Announcement of collective performance briefing meeting

The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records, misleading statements or misleading statements.

serious omissions, and shall bear legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Important content reminder:

 Meeting time: September 16, 2026 (Wednesday) 15:00-17:00 pm

 Meeting place: Shanghai Stock Exchange SSE Roadshow Center (http://roadshow.sseinfo.com)  Meeting method: SSE Roadshow Center online interaction

 Investors can log in to the homepage of the Shanghai Securities Roadshow Center website before 16:00 on September 9, 2026 (Wednesday) to September 15 (Tuesday) and click on the "Question Pre-Solicitation" column or ask questions through the company's email address [email protected]. The company will answer questions of common concern to investors at the briefing.

Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. (hereinafter referred to as the "Company") has disclosed the company's 2026 semi-annual report on the website of the Shanghai Stock Exchange (www.sse.com.cn) on August 15, 2026. In order to facilitate investors to have a comprehensive and in-depth understanding of the company's operating results, financial status and development philosophy for the first half of 2026, the company will participate in the 2026 Semi-annual Science and Technology Innovation Board Innovative Drug Industry Collective Performance Briefing hosted by the Shanghai Stock Exchange. This event will be held in an online interactive manner. Investors can log in to the Shanghai Stock Exchange's SSE Roadshow Center (http://roadshow.sseinfo.com) to participate in online interactive communication.

  1. Type of briefing session

This investor briefing will be held in an interactive online format. The company will interact and communicate with investors on the specific operating results and financial indicators for the first half of 2026, and answer questions of common concern to investors within the scope permitted by information disclosure.

1/3

  1. Time and place of the briefing meeting

(1) Meeting time: September 16, 2026 (Wednesday) 15:00-17:00

(2) Meeting location: SSE Roadshow Center (http://roadshow.sseinfo.com)

(3) Meeting method: Shanghai Securities Roadshow Center online interaction

  1. Participants

Chairman, Executive Director, Secretary of the Board of Directors (acting): Mr. Zhao Dajun

Executive Director, General Manager, Financial Director: Ms. Xue Yan

Independent non-executive director: Mr. Xu Peilong

(If there are special circumstances, participants may make adjustments.)

  1. How investors participate

(1) Investors can log in to the SSE Roadshow Center of the Shanghai Stock Exchange (http://roadshow.sseinfo.com) at 15:00-17:00 on September 16, 2026 (Wednesday) to participate in this performance briefing online. The company will answer investors’ questions in a timely manner.

(2) Investors can log in to the homepage of the SSE Roadshow Center website before 16:00 on September 9, 2026 (Wednesday) to September 15 (Tuesday), click on the "Question Pre-Collection" column (https://roadshow.sseinfo.com/questionCollection.do), and select this event according to the event time or via the company email [email protected] Ask the company questions and the company will answer questions of common concern to investors at the briefing.

  1. Contact persons and consultation methods

Contact department: Office of the Secretary of the Board of Directors

Contact number: 021-58553583

Email: [email protected]

  1. Other matters

After the investor briefing is held, investors can check the status and main content of the investor briefing through the Shanghai Stock Exchange Roadshow Center (http://roadshow.sseinfo.com).

Announcement is hereby made.

2/3

Board of Directors of Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd.

September 5, 2026

3/3